123 related articles for article (PubMed ID: 33512855)
1. Branched Multipeptide-combined Adjuvants Potentially Improve the Antitumor Effects on Glioblastoma.
Tran TA; Kim YH; Jung S; Kim IY; Moon KS; Jang WY; Lee HJ; Lee JJ; Jung TY
J Immunother; 2021 May; 44(4):151-161. PubMed ID: 33512855
[TBL] [Abstract][Full Text] [Related]
2. Branched multipeptide immunotherapy for glioblastoma using human leukocyte antigen-A*0201-restricted cytotoxic T-lymphocyte epitopes from ERBB2, BIRC5 and CD99.
Kim YH; Tran TA; Lee HJ; Jung SI; Lee JJ; Jang WY; Moon KS; Kim IY; Jung S; Jung TY
Oncotarget; 2016 Aug; 7(31):50535-50547. PubMed ID: 27409668
[TBL] [Abstract][Full Text] [Related]
3. Peptide Vaccine Combined Adjuvants Modulate Anti-tumor Effects of Radiation in Glioblastoma Mouse Model.
Tran TA; Kim YH; Duong TH; Jung S; Kim IY; Moon KS; Jang WY; Lee HJ; Lee JJ; Jung TY
Front Immunol; 2020; 11():1165. PubMed ID: 32733437
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of dendritic cell-based vaccine against glioblastoma by using cytoplasmic transduction peptide (CTP)-fused protein antigens combined with anti-PD1.
Kim YH; Tran TA; Duong TH; Jung S; Kim IY; Moon KS; Jang WY; Lee HJ; Lee JJ; Jung TY
Hum Vaccin Immunother; 2020 Nov; 16(11):2840-2848. PubMed ID: 32401608
[TBL] [Abstract][Full Text] [Related]
5. The long multi-epitope peptide vaccine combined with adjuvants improved the therapeutic effects in a glioblastoma mouse model.
Tran TA; Kim YH; Kim GE; Jung S; Kim IY; Moon KS; Kim YJ; Lee TK; Yun H; Lee JJ; Lee HJ; Lee CW; Jung TY
Front Immunol; 2022; 13():1007285. PubMed ID: 36439089
[TBL] [Abstract][Full Text] [Related]
6. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
Yamaguchi H; Tanaka F; Ohta M; Inoue H; Mori M
Clin Cancer Res; 2004 Feb; 10(3):890-6. PubMed ID: 14871964
[TBL] [Abstract][Full Text] [Related]
7. Tumor antigen-specific T cells for immune monitoring of dendritic cell-treated glioblastoma patients.
Müller I; Altherr D; Eyrich M; Flesch B; Friedmann KS; Ketter R; Oertel J; Schwarz EC; Technau A; Urbschat S; Eichler H
Cytotherapy; 2016 Sep; 18(9):1146-61. PubMed ID: 27424145
[TBL] [Abstract][Full Text] [Related]
8. AIM-2: a novel tumor antigen is expressed and presented by human glioma cells.
Liu G; Yu JS; Zeng G; Yin D; Xie D; Black KL; Ying H
J Immunother; 2004; 27(3):220-6. PubMed ID: 15076139
[TBL] [Abstract][Full Text] [Related]
9. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.
Liu G; Ying H; Zeng G; Wheeler CJ; Black KL; Yu JS
Cancer Res; 2004 Jul; 64(14):4980-6. PubMed ID: 15256472
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy.
Teramoto K; Ohshio Y; Fujita T; Hanaoka J; Kontani K
J Cancer Res Clin Oncol; 2013 May; 139(5):861-70. PubMed ID: 23411688
[TBL] [Abstract][Full Text] [Related]
11. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel human leukocyte antigen-A*0201-restricted, cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy.
Ji J; Judkowski VA; Liu G; Wang H; Bunying A; Li Z; Xu M; Bender J; Pinilla C; Yu JS
Stem Cells Transl Med; 2014 Mar; 3(3):356-64. PubMed ID: 24375541
[TBL] [Abstract][Full Text] [Related]
13. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
Front Immunol; 2021; 12():637146. PubMed ID: 34025646
[TBL] [Abstract][Full Text] [Related]
14. Cytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptide.
Matsunaga K; Nakao M; Masuoka K; Inoue Y; Gouhara R; Imaizumi T; Nishizaka S; Itoh K
Jpn J Cancer Res; 1999 Sep; 90(9):1007-15. PubMed ID: 10551332
[TBL] [Abstract][Full Text] [Related]
15. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions.
Avril T; Saikali S; Vauleon E; Jary A; Hamlat A; De Tayrac M; Mosser J; Quillien V
J Neuroimmunol; 2010 Aug; 225(1-2):22-33. PubMed ID: 20493562
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
17. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment.
Song L; Yang MC; Knoff J; Wu TC; Hung CF
PLoS One; 2014; 9(12):e115711. PubMed ID: 25531529
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma.
Maggio D; Ho WS; Breese R; Walbridge S; Wang H; Cui J; Heiss JD; Gilbert MR; Kovach JS; Lu RO; Zhuang Z
J Neurooncol; 2020 Jun; 148(2):231-244. PubMed ID: 32342332
[TBL] [Abstract][Full Text] [Related]
20. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.
Speranza MC; Passaro C; Ricklefs F; Kasai K; Klein SR; Nakashima H; Kaufmann JK; Ahmed AK; Nowicki MO; Obi P; Bronisz A; Aguilar-Cordova E; Aguilar LK; Guzik BW; Breakefield X; Weissleder R; Freeman GJ; Reardon DA; Wen PY; Chiocca EA; Lawler SE
Neuro Oncol; 2018 Jan; 20(2):225-235. PubMed ID: 29016938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
